Skip Navigation

European Heart Journal 2002 23(5):345-347; doi:10.1053/euhj.2001.2905
Copyright © 2002 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Blake, G.J.
Right arrow Articles by Ridker, P.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blake, G.J.
Right arrow Articles by Ridker, P.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorials

Tumour necrosis factor-{alpha}, inflammatory biomarkers, and atherogenesis

G.J. Blake and P.M. Ridker

Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Boston, MA, U.S.A.

References

  1. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126[Free Full Text]
  2. Skoog T, Dichtl W, Boquist S. Plasma tumour necrosis factor-{alpha} and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J. 2002;23:376–383[Abstract/Free Full Text]
  3. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–241[Abstract]
  4. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 1992;92:2303–2312
  5. Hegewisch S, Weh HJ, Hossfeld DK. TNF-induced cardiomyopathy. Lancet. 1990;335:294–295[ISI][Medline]
  6. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol. 1993;94:145–149[ISI][Medline]
  7. Moreland LW, Baumgartner SW, Schiff MH. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997;337:141–147[Abstract/Free Full Text]
  8. Moreland LW, Schiff MH, Baumgartner SW. Etanercept therapy in rheumatoid arthirits. A randomised, controlled trial. Ann Intern Med. 1999;130:478–486[Abstract/Free Full Text]
  9. Elliott MJ, Maini RN, Feldmann M. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105–1110[CrossRef][ISI][Medline]
  10. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101:2149–2153[Abstract/Free Full Text]
  11. Hwang SJ, Ballantyne CM, Sharrett AR. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:4219–4225[Abstract/Free Full Text]
  12. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88–92[CrossRef][ISI][Medline]
  13. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491–495[Abstract/Free Full Text]
  14. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–1772[Abstract/Free Full Text]
  15. Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine. 1992;4:361–368[CrossRef][ISI][Medline]
  16. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102:2165–2168[Abstract/Free Full Text]
  17. Pasceri V, Willerson JT, Yeh ET. Modulation of c-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531–2534[Abstract/Free Full Text]
  18. Ridker PM. High-sensitivity C-reactive protein (hs-CRP): A potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001;103:1813–1818[Abstract/Free Full Text]
  19. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843[Abstract/Free Full Text]
  20. Albert M, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE). A Randomized Trial and Cohort Study. JAMA. 2001;286:64–70[Abstract/Free Full Text]
  21. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive c-reactive protein levels. Circulation. 2001;103:1933–1935[Abstract/Free Full Text]
  22. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230–235[Abstract/Free Full Text]
  23. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191–1193[Abstract/Free Full Text]
  24. Ridker PM, Rifai N, Pfeffer MA. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1998;98:839–844[Abstract/Free Full Text]
  25. Ridker PM, Rifai N, Clearfield M. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344:1959–1965[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. F. Pasini, M. Anselmi, U. Garbin, E. Franchi, C. Stranieri, M.C. Nava, V. Boccioletti, C. Vassanelli, and L. Cominacini
Enhanced Levels of Oxidized Low-Density Lipoprotein Prime Monocytes to Cytokine Overproduction via Upregulation of CD14 and Toll-Like Receptor 4 in Unstable Angina
Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1991 - 1997.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
T Kilic, D Ural, E Ural, Z Yumuk, A Agacdiken, T Sahin, G Kahraman, G Kozdag, A Vural, and B Komsuoglu
Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome
Heart, August 1, 2006; 92(8): 1041 - 1046.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
I. A. Arenas, Y. Xu, and S. T. Davidge
Age-associated impairment in vasorelaxation to fluid shear stress in the female vasculature is improved by TNF-{alpha} antagonism
Am J Physiol Heart Circ Physiol, March 1, 2006; 290(3): H1259 - H1263.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. D. S. A. Wansa, J. M. Harris, G. Yan, P. Ordentlich, and G. E. O. Muscat
The AF-1 Domain of the Orphan Nuclear Receptor NOR-1 Mediates Trans-activation, Coactivator Recruitment, and Activation by the Purine Anti-metabolite 6-Mercaptopurine
J. Biol. Chem., June 27, 2003; 278(27): 24776 - 24790.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C.-H. Wang, S.-H. Li, R. D. Weisel, P. W.M. Fedak, A. S. Dumont, P. Szmitko, R.-K. Li, D. A.G. Mickle, and S. Verma
C-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle
Circulation, April 8, 2003; 107(13): 1783 - 1790.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Blake, G.J.
Right arrow Articles by Ridker, P.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blake, G.J.
Right arrow Articles by Ridker, P.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?